LFA
TTNP

Level Financial Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Level Financial Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-49
Closed -$407 – 241
2023
Q4 		$407 Hold
49
– – ﹤0.01% 261
2023
Q3 		$468 Hold
49
– – ﹤0.01% 271
2023
Q2 		$638 Hold
49
– – ﹤0.01% 268
2023
Q1 		$819 Hold
49
– – ﹤0.01% 226
2022
Q4 		$1K Hold
49
– – ﹤0.01% 268
2022
Q3 		$1K Hold
49
– – ﹤0.01% 238
2022
Q2 		$1K Hold
49
– – ﹤0.01% 286
2022
Q1 		$1K Hold
49
– – ﹤0.01% 224
2021
Q4 		$1K Buy
+49
New +$1.48K ﹤0.01% 260

Other funds holding TTNP

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Level Financial Advisors's TTNP Position: Q1 2024 in Review

Level Financial Advisors sold out of Titan Pharmaceuticals (TTNP) in Q1 2024, closing a stake of 49 shares — an estimated $407 sold.

Level Financial Advisors first reported a position in TTNP in Q4 2021 and held it in 9 quarters. The position peaked at $1K in Q4 2022. 17 funds tracked by Wall St. Rank hold TTNP as of Q1 2024.

  • Level Financial Advisors reported no remaining Titan Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Level Financial Advisors sold 49 Titan Pharmaceuticals shares in Q1 2024, an estimated $407.
  • Level Financial Advisors first reported a position in Titan Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Level Financial Advisors's Titan Pharmaceuticals position peaked at $1K in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2024.

Based on Level Financial Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.